Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of MKC-1 administered twice daily for 14 consecutive days every 4 weeks in patients with recurrent or resistant epithelial ovarian cancer or advanced endometrial cancer.

Next Previous
Search
Trial Profile

A phase 2 study of MKC-1 administered twice daily for 14 consecutive days every 4 weeks in patients with recurrent or resistant epithelial ovarian cancer or advanced endometrial cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MKC 1 (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals

Most Recent Events

  • 19 Jan 2012 Actual patient number (44) added as reported by ClinicalTrials.gov.
  • 19 Jan 2012 Actual end date (1 Jan 2012 ) added as reported by ClinicalTrials.gov.
  • 19 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top